Skip to main content

Table 2 TMEM240 mRNA expression and promoter hypermethylation in relation to the clinical parameters of breast cancer from TCGAa

From: Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

Characteristics

Total

TMEM240 mRNAb

TMEM240 methylation

  

Low n (%)

High n (%)

Low n(%)

High n(%)

Overall

714

427 (59.8)

287 (40.2)

582

351 (60.3)

231 (39.7)

Age

761

        

 < 65

551

331 (60.1)

220 (39.9)

453

264 (58.3)

189 (141.7)

 ≥65

210

127 (60.5)

83 (39.5)

170

108 (63.5)

251 (40.3)

Race

525

       

 White

421

259 (61.5)

162 (38.5)

338

234 (69.2)

104 (30.8)

 Black/African American

72

41 (56.9)

31 (43.1)

64

19 (29.7)

45 (70.3)

 Asian

32

27 (84.4)

5 (15.6)0.022

31

14 (45.2)

17 (54.8) <0.001

Menopause state

480

       

 Premenopause

123

76 (61.8)

47 (38.2)

103

69 (67.0)

34 (33.0)

 Perimenopause

16

9 (56.3)

7 (43.8)

14

6 (42.9)

8 (57.1)

 Postmenopause

341

218 (63.9)

123 (36.1)

287

174

(60.6)

113 (39.4)

Histological type

714

        

 ILC

170

65 (38.2)

105 (61.8)

152

113 (74.3)

39 (25.7)

 IDC

504

341 (67.7)

163 (32.3)<0.001

400

215 (58.8)

185 (46.3)<0.001

 Mucinous carcinoma

15

8 (53.3)

7 (46.7)

14

11 (78.6)

3 (21.4)

 Mixed type

25

13 (52.0)

12 (48.0)

16

12 (75.0)

4 (25.0)

Tumor stage

535

        

 I and II

385

247 (64.2)

138 (35.8)

311

189 (60.8)

122 (39.2)

 III and IV

150

86 (57.3)

64 (42.7)

129

80 (62.0)

49 (38.0)

Tumor Size

539

        

 T0–T1

137

93 (67.9)

44 (32.1)

114

80 (70.2)

34 (29.8)

 T2–T4

402

243 (60.4)

159 (39.6)

329

191 (58.1)

138 (41.9)0.022

ER

535

        

 Negative

117

84 (71.8)

33 (28.2)0.023

103

22 (21.4)

81 (78.6)<0.001

 Positive

418

252

(60.3)

166 (39.7)

340

49 (73.2)

91 (26.8)

PR

533

        

 Negative

169

118 (69.8)

51 (30.2)0.020

143

45 (31.5)

98 (68.5)<0.001

 Positive

364

216 (59.3)

148 (40.7)

299

225 (75.3)

74 (24.7)

HER2

463

        

 Negative

404

245 (60.6)

159 (39.4)

340

220 (64.7)

120 (35.3)

 Positive

59

41 (69.5)

18 (30.5)

45

20 (44.4)

25 (55.6)0.008

TNBC

515

       

 Yes

76

54 (71.1)

22 (28.9)

68

13 (19.1)

55 (80.9)<0.001

 No

439

267 (60.8)

172 (39.2)

358

255 (71.2)

103 (28.8)

  1. aThese results were analyzed by the Pearson X2 test. P values with significance are shown as superscripts
  2. bWhen the TMEM240 expression level in breast tumors was less than half of the mean of TMEM240 expression levels in adjacent normal breast tissues was defined as low expression from TCGA data set using RNA sequencing analysis